Q3 2023 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Conclusions
Financial performance
Immunology
ianalumab - BAFF-R inhibitor
NCT03217422 AMBER (CVAY736B2201)
Indication
Autoimmune hepatitis
Phase 2
Phase
Patients
68
Primary
Alanine aminotransferase (ALT) normalization
Outcome
Measures
Arms
VAY736
Intervention
Placebo control with conversion to active VAY736
Target
Patients
Autoimmune hepatitis patients with incomplete response or intolerant to
standard treatment of care
Readout
2024
Milestone(s)
Publication
TBD
55 Investor Relations | Q3 2023 Results
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
ianalumab - BAFF-R inhibitor
NCT05126277 SIRIUS-LN (CVAY736K12301)
Lupus Nephritis
Phase 3
Indication
Phase
Patients
420
Primary
Outcome
Measures
Arms
Intervention
References
Abbreviations
Other
Frequency and percentage of participants achieving complete renal response
(CRR) [ Time Frame: week 72]
Arm 1: Experimental - ianalumab s.c. q4w in addition to standard of care (SoC)
Arm 2: Experiemental - ianalumab s.c. q12w in addition to SoC
Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC
Patients with active Lupus Nephritis
Target
Patients
Readout
Milestone(s)
Publication
Primary 2027
TBD
NOVARTIS | Reimagining MedicineView entire presentation